US › Healthcare

Uniqure NV (QURE)

US · Healthcare · Biotechnology

$43.68-0.86%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$5.8M
Revenue YoY
+11.0%
Net profit
$-81.1M
Profit YoY
-114.9%
EPS
$-1.22
EPS estimate
$-0.81
Net margin
-1,387.8%

EPS came in at -1.22 against a street estimate of -0.81 — a miss of 50.6%.

Key statistics

Market cap
$3.03B
Forward P/E
27.9
P/B
9.35
Book value
$4.67
EPS (TTM)
$-4.07
52-week high
$71.50
52-week low
$8.73
50-day MA
$36.72
200-day MA
$28.54
Beta
0.90

Analyst view

Analysts rate Uniqure NV a strong buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $68.16.

Shareholding

Insiders
1.26%
Institutions
84.84%

Largest institutional holders

FundStake
venBio Select Advisor LLC8.59%
Aberdeen Group PLC7.65%
JPMorgan Chase & Co4.09%
Two Sigma Investments LLC3.86%
RTW INVESTMENTS, LLC3.73%
State Street Corp3.26%
Orbimed Advisors, LLC3.08%
FMR Inc2.51%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-07-29
Results announced · Q3 20262026-07-29
Material agreement · Q2 20262026-06-24
Reg FD disclosure · Q2 20262026-06-22
Company announcement · Q2 20262026-06-17
Quarterly report · Q1 20262026-05-05
Proxy statement · Q2 20262026-04-27
Annual report FY20252026-03-02

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Uniqure NV — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.